Recruiting PHASE1 INTERVENTIONAL 5-arm
NCT07377045
Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma
Phase 1b Dose Escalation Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma
Sponsor: Oncomatryx Biopharma S.L.
Conditions
Pancreatic Adenocarcinoma Metastatic
Interventions
Nab-paclitaxel + Gemcitabine OMTX705 Tislelizumab (i.v. 200mg)
Updated 1 time since 2026 Last updated: Jan 21, 2026 Started: Oct 28, 2025 Primary completion: Mar 31, 2029 Completion: Mar 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Pancreatic Adenocarcinoma Metastatic and is currently actively recruiting participants. Oncomatryx Biopharma S.L. leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Oncomatryx Biopharma S.L.
Data source: Oncomatryx Biopharma S.L.
For direct contact, visit the study record on ClinicalTrials.gov .